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Abstract
Background: The effect of intensive smoking cessation programs on postoperative complications has never before
been assessed in soft tissue surgery when smoking cessation is initiated on the day of surgery.
Methods: A single-blinded randomized clinical trial conducted at two vascular surgery departments in Denmark.
The intervention group was offered the Gold Standard Program (GSP) for smoking cessation intervention. The
control group was offered the departments’ standard care. Inclusion criteria were patients with planned open
peripheral vascular surgery and who were daily smokers. According to the power calculation a total of 144 patients
were needed in the trial.
Results: Due to slow patient inclusion, the trial was terminated prior to fulfilling the power calculation. Thirty-two
patients were included in the trial from March 2011 to September 2012. Of these, 11 were randomized to the GSP
intervention and 21 as controls. There was no difference in 30-day complication rates or 6-week abstinence rates
between the two groups.
Conclusions: A trial assessing the effect of smoking cessation on postoperative complications on the day of soft
tissue surgery is still needed. If another trial is to be planned it must be more pragmatic with less extended inclusion
criteria and conducted nationally or internationally to ensure enough patients for the trial.
Trial registration: ClinicalTrials.gov (NCT01469091). Registration date: 27 October 2011.
Keywords: Randomized clinical trial, Gold Standard Program, Smoking cessation, Postoperative complications,
Peripheral vascular surgery
Background
Smoking is a well-known risk factor for developing com-
plications after surgery. The reason that smoking to-
bacco is a risk factor for developing postoperative
complications is multifactorial. The tobacco and the ad-
ditives affect most cells and tissues in the body. Wound
healing is slower due to diminished oxygenation of the
tissues, impaired microcirculation and release of vaso-
active components [1, 2]. Electrocardiograms studied
during surgery in smokers have shown signs of heart
muscle ischemia [3, 4]. Smoking is a well-known risk
factor for developing chronic obstructive pulmonary dis-
ease (COPD), but even in smokers with normal lung
function the tobacco smoke also impairs the movement
of the cilia in the bronchioles and bronchus causing
stagnation of secretion and with fewer macrophages
than in non-smokers, all adding to an increased risk of
pneumonia [5, 6].
Three studies have shown that intensive smoking ces-
sation programs 4–8 weeks prior to surgery reduced
postoperative complications significantly [7–9]. Even in
the acute setting, a significant effect of smoking cessa-
tion intervention has been shown on results of acute
fracture surgery [10].
The vascular patient population is often perceived as
more heavy smokers than the general smoker population
and therefore possibly also has increased risk of
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postoperative complications when in need of surgery.
Smoking cessation intervention among vascular sur-
gical candidates might therefore be additionally chal-
lenging, but has not previously been reported.
We decided to set up a randomised controlled trial to
assess the effect of an intensive smoking cessation pro-
gram on results of acute vascular surgery. We intended
to include patients on the day of admission and to insti-
tute the smoking cessation program during the immedi-
ate postoperative period. The primary outcome was the
occurrence of perioperative complications, and among
the secondary outcomes we were particularly interested
in whether patients remained abstinent from the day of
surgery until 6 weeks after surgery.
Methods
Design
The trial was designed as a clinical controlled single-
blinded randomized trial. It was registered in Clinical-
Trials.gov (NCT01469091), registration date October 27,
2011, and approved by the Danish National committee
on Health Research Ethics (H-1-2010-112).
Setting
This trial was conducted at the two departments of vas-
cular surgery at Rigshospitalet and Gentofte Hospital,
Copenhagen, and at Lillebaelt Hospital (former Kolding
Hospital). The departments serve as primary referral for
vascular diseases of 2½ million people corresponding to
2/5 of the Danish population.
A pilot study from the Danish National Vascular
Registry showed that the number of patients fulfilling
the inclusion criteria was 144 in the year prior to the
project start.
The trial was initiated in March 2011 in Copenhagen
for patients admitted acutely and operated on for per-
ipheral arterial surgery within 72 hours of admittance
(phase 1). Due to slow patient inclusion the vascular de-
partment at Lillebaelt Hospital was enrolled in the pro-
ject as of August 2011. By January 1, 2012 the project
was extended to include also patients admitted for elect-
ive peripheral arterial surgery (phase 2).
Participants
Inclusion criteria were daily smokers admitted for pri-
mary open infrainguinal arterial surgery. Initially only
patients admitted acutely and operated upon within
72 hours were included, but as described above, patients
admitted for elective surgery were included also during
phase 2 of the trial.
Exclusion criteria were alcohol consumptions of more
than 35 units a week, being pregnant or patients youn-
ger than 20 years. Also patients who had been operated
upon in the same vascular segment within 90 days were
excluded, as well as patients who could not give in-
formed consent.
Patients who had quit smoking within 3 days of admit-
tance were considered smokers and were eligible for
inclusion.
Randomisation
The Section of Biostatistics, University of Copenhagen
made a list with randomization numbers, stratified for
each of the two departments. The patients were random-
ized in a 1:1 ratio for the intervention or the control
group in blocks of ten. The envelopes used were opaque
and sealed and were numbered consecutively. A doctor
at the department, who was not involved in the trial,
kept the randomization list in a locked drawer until the
trial was terminated, all follow-ups had been conducted
and data were registered.
The vascular departments’ doctor on duty gave all pa-
tients eligible for inclusion oral and written information
of the project at the time of admittance. All patients
gave a written form of consent before inclusion. The de-
partments’ doctor on duty also performed the random-
isation. Whether the participants were randomized to
intervention or control group was open to the nursing
staff and the doctor performing the randomization, but
was blinded for the examining and data-collecting doc-
tor in the outpatient clinic.
At the primary investigators’ department all admit-
tance records were screened several times a week to
identify potential participants who had not been in-
formed about the trial.
Within 72 hours after surgery the patients included in
the trial were offered supplementary information by the
primary investigator or project nurse, to make sure they
had received and understood the information on the
project.
Intervention
Patients who were randomized to smoking cessation
intervention were offered the Gold Standard Program
(GSP) that has been the smoking cessation program of
choice in Denmark since 2001. It is an intensive smoking
cessation program developed by the National Cancer So-
ciety and the National Stop Smoking Centre [11] to im-
prove and standardize smoking cessation programs in
Denmark. It consists of a standard program with five
meetings over 6 weeks where each meeting is predefined
with motivational conversation, smoking habits and edu-
cation on the hazardous effects of smoking as well as
the benefit of successful quitting. Other meetings revolve
around risks of relapse, thoughts and reflections on quit-
ting, challenges during and after the course. The first
meeting was within 48 hours after surgery depending on
the patient and the project nurse. At the first meeting
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the patients were scored using the Fagerström Test for
nicotine dependence [12] and the number of cigarettes
smoked per day was recorded. Accordingly, they were
recommended the dosage of nicotine replacement ther-
apy, if interested. Together with the smoking cessation
instructor they decided which administration form of
nicotine replacement therapy could be useful. Nicotine
gum, patches, inhalators and microtabs were available
for the participants. Nicotine replacement therapy is the
primary recommendation for smoking cessation inter-
vention in Denmark [11]. No other medical replacement
was offered (i.e., bupropion/varenicline). Normally, the
GSP is free of charge but patients must themselves pay
for the nicotine replacement and the course is offered as
group- or individual-based. We offered free nicotine re-
placement and individual meetings to all participants
randomized for the GSP corresponding to the previous
studies on GSP for surgical patients [8–10]. Three
nurses from the outpatient clinics, all trained smoking
cessation instructors according to the GSP, were respon-
sible for the smoking cessation meetings and patients
were classified ‘compliant with program’ if they partici-
pated in at least 75 % of the meetings.
Additional to the information about the trial, given
by the admitting doctor, the control group was of-
fered the hospital departments’ standard care. This
could be anything from no information on smoking
cessation to the admitting doctor’s bedside informa-
tion about the risk of smoking and the benefits of
quitting. The control group was also offered free
nicotine replacement during admittance as part of the
departments’ standard care, but after discharge it was
the patients’ responsibility to seek further help to
smoking cessation if they wished.
After surgery and discharge all participants were seen
in the outpatient clinic for a 6-week follow-up at the end
of the GSP, a 3-month follow-up and 1-year follow-up to
examine the effect of the operation performed, to regis-
ter any complications and to assess the participants
smoking status.
Data
After written informed consent was given, data was col-
lected for the case-report file: gender, age, cigarettes
smoked per day, type of surgery (acute versus elective),
educational level and working status. Patients also an-
swered the short form 36 (SF-36), which is a question-
naire with 36 questions concerning quality of life and
health care. Measure points are both physical and men-
tal health [13].
After discharge and at follow-up in the outpatient
clinic any complication requiring treatment was re-
corded. Again the questionnaire SF-36 was filled in and
smoking status was obtained. Smoking status was self-
reported as well as validated by carbon monoxide breath
test.
Outcome
The primary outcome was occurrence of postoperative
complications requiring treatment within 30 days post-
operatively. Complications were classified into four
groups according to the Danish National Vascular
Registry [14]:
 Wound complications (infection, lymphorrhea,
necrosis)
 Surgical complications (bleeding, emboli/thrombosis
of the reconstruction, peripheral nerve lesion, ileus
or ischemia of bowels)
 General complications (cardiac or pulmonary
complications, dialysis, transitory cerebral ischemia
or stroke, deep venous thrombosis, compartment
syndrome, urinary tract syndrome and multiorgan
dysfunction syndrome)
 Death ≤ 30 days
Secondary outcomes were:
 Patency of reconstruction, 30 days and 1 year
postoperatively
 Amputation rate, 30 days and 1 year postoperatively
 Length of stay (LOS)
 Continuous tobacco abstinence 6 weeks, 3 months
and 1 year
 Physical and mental health according to SF-36,
6 weeks, 3 months and 1 year
 Time to return to normal activity
Statistical analysis
Power calculation of the sample size was performed
using the formula: N > (Z2α + Z2β)2 × S
2 /minimum rele-
vant difference (MIREDIF). With 2α = 5 % and 1-β =
80 % and the MIREDIF = 0.2. The power analysis of the
sample size assessed that 144 patients should be in-
cluded in the trial, 72 in the intervention group and 72
in the control group. Analyses of the postoperative re-
sults were done by using SPSS version 22 (IBM Corp.,
Armonk, NY, USA). The variables were assessed using
Fisher’s exact test (two-sided).
Results
Due to lack of patient inclusion, the trial was terminated
prematurely prior to reaching the number of patients
prespecified in the power calculation. Recruitment for
the trial was terminated by the end of September 2012.
At that point, we had succeeded in recruiting 21 patients
in Copenhagen over 19 months and 11 patients in Kolding
over 14 months.
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Within the chosen time period, a total of 817 poten-
tially eligible patients were admitted to the participating
vascular departments for peripheral arterial surgery. Of
these, 248 patients were admitted during phase 1 (acute/
subacute) and 569 patients were admitted during phase
2 (acute/subacute and elective) (Fig. 1).
A total of 308 (38 %) were current smokers. However,
the following had to be excluded according to the cri-
teria: surgery performed as an elective procedure (20 pa-
tients, during phase 1), readmitted and operated upon in
the same vascular segment within the previous 90 days
(17 + 76 patients), drinking more than 5 units/day (26 +
56 patients), and finally six patients in whom data were
missing (Fig. 1).
This left 107 patients eligible for inclusion. A total of 34
patients refused to take part in the trial and another 41 pa-
tients were not asked, for logistical reasons. At the depart-
ment where the primary investigator was working full-
time with the trial and screened admittance records sev-
eral times weekly, 12 patients were not asked throughout
the trial period (19 months) due to courses and vacations.
At the second department, the investigator was only in-
volved in the project part-time and missed 29 patients
throughout the trial period (14 months) due to courses,
vacations and because of the work schedule.
Of the 32 patients recruited for the trial, 11 were
randomized to the GSP intervention and 21 were ran-
domized as controls. In the control group, one patient
Fig. 1 Flow chart for patient eligibility and inclusion. Phase 1: 1 March 2011 to 31 December 2011, acute/subacute admittance. Phase 2: 1 January
2012 to 30 September 2012, acute/subacute and elective admittance
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withdrew consent to participate the day after inclusion
and three patients were excluded because they had
aortic surgery and not infrainguinal surgery. This left 11
patients for GSP intervention and 17 patients in the
control group (Fig. 2). For the Consort 2010 checklist
and flow diagram, see Additional files 1 and 2.
The median age of the patients in the GSP interven-
tion group was 61 years versus 65 years in the control
group. The median number of days in hospital was
9 days for the GSP patients and 7 in the control group.
Cigarette status at admittance showed that 64 % smoked
more than 20 cigarettes per day in the GSP intervention
group compared to only 18 % in the control group (p =
0.02). In the intervention group, the preferred nicotine
replacement of choice was combined long-term-acting
and fast-acting therapy – thus following the general rec-
ommendation on nicotine replacement therapy. Overall,
nine participants used patches (25 mg/16 hours: six par-
ticipants, 20 mg/16 hours: one participant, 15 mg/
16 hours: two participants). All but one combined with
gum, inhalators or microtabs. Only two participants in
the intervention group did not choose any nicotine re-
placement therapy. For the rest of the demographic data
see Table 1.
The peripheral vascular procedures performed were
bypass from the femoral artery to the popliteal artery
and branches (intervention/complication group: 46 %/
47 %), thrombectomies of the femoral arteries and pop-
liteal artery (9 %/24 %), transendarterectomies of the
femoral arteries (27 %/24 %) and femorofemoral cross-
over bypass (18 %/5 %), see Table 2.
In both groups there were recorded eight complica-
tions in seven patients (p = 0.44) within the first 30 days.
Patients in the GSP intervention group were compliant
with the smoking cessation program in 73 % of cases.
Smoking abstinence after 6 weeks was achieved in three
of 11 (27 %) patients in the GSP intervention group and in
three of 17 (18 %) patients in the control group (Table 3).
One patient died due to an oral cancer 11 months postop-
eratively and two patients were transfemoral amputated at
4 and 7 months respectively. All three patients were ran-
domized to the GSP intervention group.
Due to the few patients included in the trial, the
secondary outcomes: patency of reconstruction, SF-36
and time to return to normal activities are not re-
ported, and we refrained from statistical testing for
any group differences.
Discussion
It was very disappointing that we eventually had to ter-
minate this trial prematurely. We succeeded in enrolling
Fig. 2 Flow chart for patient inclusion, randomization and completion of the trial
Table 1 Demographics for the GSP intervention group and
control group
GSP intervention Control group
Number of patients: N = 11 N = 17
Age (years) 61 (39–72) 65 (52–80)
Male gender 9 (82) 13 (76)
Acute operation 6 (55) 8 (50)
Cigarettes per day 22 (10–50) 14 (2–50)
Educational level:
Missing information 3 3
Primary school 5 (45) 9 (53)
High school/college/university 3 (27) 5 (29)
Occupation:
Missing information 1
Working 2 (18) 4 (24)
Retired 9 (82) 12 (71)
Data are from time of inclusion, given as number (%) or median (range)
GSP Gold Standard Program
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only 32 of the planned 144 (22 %) patients during a time
period of 19 months.
Our observation was that out of 817 patients admitted
for acute or elective peripheral arterial surgery only 107
were eligible for inclusion (Fig. 1) and of the 66 patients
asked 52 % did not wish to participate, which correlates
well with the declining rate of comparable trials (40–
62 %) [8, 10]. All of the eligible patients who declined
gave more or less the same reason for declining: they
wanted to quit smoking but they were not interested in
following a smoking cessation program. There were 41
eligible participants who were not asked to participate
for logistical reasons such as courses, vacations and
work schedules of the investigators.
We ask ourselves whether we could have foreseen the
difficulties in recruiting patients for this trial.
In designing the trial, reflections were made on the
group of patients included. Patients having open abdom-
inal vascular surgery, i.e., aortic surgery, were excluded
due to the different surgical procedures, different profile
of postoperative complications and a higher mortality
[15, 16] than that of peripheral vascular surgery. Like-
wise, the increasing group of patients undergoing endo-
vascular procedures was not included, since the surgical
trauma is usually of very moderate size and the proced-
ure is done under local anesthesia. Both reduce the risk
of postoperative complications compared to open sur-
gery and the complication rate after endovascular proce-
dures is reported about 5–10 % [17, 18]. The number of
patients to be included in a corresponding study on
endovascular-treated patients would be nearly 1000.
Therefore, broadening the inclusion criteria to other sur-
gical procedures would have made the trial much more
demanding, we thought.
A reduction of the exclusion criteria was also consid-
ered. A relatively large fraction of the patients who
smoked consumed more than 5 units of alcohol per day,
which per se increases the risk of complications signifi-
cantly [19–21], and the hypothesis did not include an
evaluation of the effect of smoking cessation interven-
tion on alcohol-induced complications after surgery.
Thus, including the hazardous drinking smokers was not
an option, even though they accounted for almost 27 %
of the 308 smokers in the trial. Furthermore, the three
previous randomised studies on GSP targeting peri-
operative smoking also excluded the hazardous drinkers
from their study population [8–10].
We also excluded patients who had been operated
upon in the same arterial segment within 90 days, but it
might have been relevant to reconsider that criterion in
spite of their greater risk of postoperative complications
[22]. It would probably have required an extra stratifica-
tion, in order to secure similar distribution in the inter-
vention and control group.
Even if smoking cessation on the day of surgery has
been shown to be able to reduce the postoperative com-
plications in orthopedic patients, it cannot be transferred
uncritically to the vascular patient population, we still
have reason to believe that the vascular patients would
benefit from smoking cessation.
Other randomized controlled trials using intensive
pre- and perioperative smoking interventions on the ef-
fect of smoking cessation on postoperative complications
have all shown a significant reduction in complications
in the intervention group [8–10, 23]. In our trial the pre-
specified number of patients was not reached, and there-
fore it was not possible to show any effect of the GSP
intervention. Thus we were unable to assess any effect
on the occurrence of perioperative complications be-
tween the two groups. Neither could we evaluate on the
secondary outcome, whether there was a difference in
smoking behavior after 6 weeks. The small number of
patients included is the reason why we have chosen not
to exercise any further statistical analysis on the data
depicted in Tables 1, 2 and 3 and why the results of the
SF-36 obtained are not reported.
We found that 27 % of the GSP intervention group as
opposed to 18 % of the control group were abstinent
during the first 6 weeks after surgery. This is lower than
the other surgical studies using the same program
Table 2 Surgical procedures performed on the GSP intervention
group and the control group
GSP intervention
group N = 11
Control
group N = 17
By-pass from the femoral artery and
branches to the popliteal artery and
branches
5 (46) 8 (47)
Thrombectomy of the femoral artery,
popliteal artery and branches
1 (9) 4 (24)
Transendarterectomy of the femoral
artery and branches
3 (27) 4 (24)
Femorofemoral crossover bypass 2 (18) 1 (5)
Numbers = N (%)
GSP Gold Standard Program
Table 3 Six-week follow-up results
GSP intervention
group N = 11
Control
group N = 17
Compliant with GSP program 8 (73) NR
Abstinent from tobacco 3 (27) 3 (18)
Wound complication, 30 days* 5 (45) 7 (41)
Surgical complication, 30 days* 3 (27) 0
General complication, 30 days* 0 1 (6)
Length of stay, days (range) 9 (4–17) 7 (2–30)
Amputation rate 0 0
Numbers = N (%)
GSP Gold Standard Program, NR not relevant
*For definitions of complications see text
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showing quit rates of 43–60 % in the GSP intervention
group compared to 10–20 % in the control group [9, 10].
Apart from the fact that the power calculation was not
met, another reason could be a weaker performance of
the GSP in the involved departments. However, all the
nurses were trained at the same national program. Co-
hort studies evaluating the GSP for smoking cessation
in real-life settings in Denmark have shown that for
heavy smokers the abstinence rate was 33 % 6 months
after intervention [24], for unemployed smokers it was
27 % versus 34 % for employed smokers 6 months after
intervention [25], and for elderly smokers > 60 years it
was 37 % 6 months after intervention [26]. The British
nationwide ‘stop smoking services’ found an overall
abstinence rate of 36 % 4 weeks after intervention [27].
These abstinence rates correlate well the abstinence
rates in the vascular patient population, but the differ-
ence between our intervention group and our control
group was not noticeable.
There may exist a clinical culture of low expectancy to
the vascular patients’ ability to quit smoking successfully,
which can influence the outcome significantly. Such a
culture is supported by the existence of smoking rooms
for patients at some of the hospitals involved. In
addition, the widespread smoking in the vascular patient
population may play a role; there are 44 % daily smokers
[15], corroborating the 38 % found in this trial, and in
contrast to the 17 % found in the Danish population, in
general [28]. From clinical experience, there is also rea-
son to believe that the vascular patient population is still
smoking, in spite of their smoke-related illness, may
smoke more heavily than the background population,
and are more stigmatized by their smoking. Last but not
least, the admitting doctor informed all eligible patients
verbally and in writing about the health benefits of
smoking cessation according to the protocol. So even if
the patients allocated to the control group did not re-
ceive the GSP, they still received more information on
the benefits of smoking cessation than when normally
admitted prior to vascular surgery, and therefore maybe
the difference of intervention between the GSP and con-
trol groups was smaller than we anticipated.
If we were to set up another trial assessing the effect
of smoking cessation on postoperative complications, we
would have to reconsider the design of the trial accord-
ing to the experiences and challenges we faced during
the execution of this trial.
As discussed above, our inclusion and exclusion cri-
teria were quite extended, giving the (expected) results
high statistical credibility and internal validity.
Designing a future trial more pragmatically could be
appropriate. A pragmatic trial would include all vascular
patients who smoke admitted for open surgery or endo-
vascular procedures (both aortic, peripheral, carotid,
endovascular, re-operations, excessive alcohol consumers,
etc.) ensuring a higher number of eligible patients. This
would increase the external validity making the results dir-
ectly applicable to the vascular community. However, such
a trial would demand inclusion of a huge number of pa-
tients followed for a longer period of time, both adding to
the cost of the trial. The larger sample size would necessi-
tate several more centers to be included. Securing the uni-
formity and quality of the smoking cessation instructors
and having devoted full-time primary investigators at each
site pose additional challenges, though not insurmountable.
Overall, smokers undergoing open vascular surgery are
still at high risk. New research must focus on risk reduc-
tion. Based on the trial, we would recommend making
sure that the smoking cessation program used is
followed by a higher level of successful quitting. Further-
more, it should be a national or international trial ensur-
ing inclusion of the number of patients needed, and
even so possibly expand the inclusion criteria and reduce
the exclusion criteria to include all vascular patients who
smoke.
The trial further inspires to develop an evaluation of a
simultaneous alcohol and smoking cessation interven-
tion program for risk reduction at surgery.
Conclusions
Including patients in the single-blinded randomized clin-
ical trial, aimed to assess whether smoking cessation on
the day of peripheral vascular surgery could reduce peri-
operative complications compared to a control group,
turned out to be more challenging than anticipated.
Even though inclusion criteria was extended from only
acute admitted patients to elective patients as well, it
was not possible to reach the patient number needed ac-
cording to the power calculation.
In the material from the small number of included pa-
tients, no difference was seen in the rate of 30-day post-
operative complications nor could we show a difference
in abstinence from smoking 6 weeks postoperatively be-
tween the two groups.
A randomized trial assessing the effect of smoking ces-
sations on the day of surgery in vascular patients is still
needed. If a trial were to be completed we would rec-
ommend it to be designed more pragmatically and
conducted nationally or internationally to ensure eli-
gible patients.
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